REGULATORY
PMDA to Continue Remote GCP/Compliance Inspections through June Next Year
The Pharmaceuticals and Medical Devices Agency (PMDA) will continue conducting remote GCP on-site inspections and paper-based compliance inspections until the end of June next year. The agency expects to announce next March whether it will continue remote inspections after that…
To read the full story
Related Article
- PMDA to Continue Remote GCP/Compliance Inspections through End of March 2021
September 24, 2020
REGULATORY
- Japan OKs Coverage for Susmed Insomnia App, Shionogi ADHD Therapy App
May 15, 2026
- MHLW’s Mori Vows to Make Japan Pharma Market “More Attractive”
May 15, 2026
- MHLW Official Says US MFN Policy Could Be Taken Up by Chuikyo
May 15, 2026
- Oncolys’ Telomelysin Up for Japan Panel Review on May 21
May 15, 2026
- Japan to Launch CEA “Technical Discussions” under MHLW Research Group
May 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





